Abivax S.A.'s stock surged 8.26% in pre-market trading, driven by positive market reaction to the company's latest financial disclosure which revealed a strong liquidity position.

The company's earnings report showed it held €491.6 million in cash, cash equivalents, and short-term investments as of March 31, with a projected cash runway extending into the fourth quarter of the following year based on current operating assumptions. This robust balance sheet directly addressed market concerns about Abivax's ability to sustain its research and development programs.

Abivax is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases, with its lead candidate obefazimod currently in Phase 3 development for the treatment of moderately to severely active ulcerative colitis. The strong financial position has boosted investor confidence in the company's ability to advance its clinical programs without near-term funding concerns.